| |
Univariable analysis
|
Multivariable analysis
|
|---|
|
HR (95% CI)
|
p-value
|
HR (95% CI)
|
p-value
|
|---|
|
Cohort I
|
|
OS
|
2.05 (1.10–3.82)
|
0.024
|
1.93 (1.03–3.62)
|
0.039
a
|
|
BCSS
|
2.34 (1.00–5.47)
|
0.051
| | |
|
RFS
|
1.88 (0.90–3.97)
|
0.095
| | |
|
Cohort II
|
|
OS
|
1.91 (1.39–2.63)
|
<0.001
|
1.61 (1.09–2.39)
|
0.018
b
|
|
BCSS
|
1.93 (1.38–2.69)
|
<0.001
|
1.58 (1.05–2.38)
|
0.027
b
|
|
RFS
|
1.75 (1.27–2.40)
|
0.001
|
1.67 (1.13–2.48)
|
0.010
b
|
- Low ANLN NF(ref) vs high ANLN NF
-
HR hazard ratio, CI confidence interval, ref referent group, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
- Significant correlations (p < 0.05) are indicated by bold numbers
-
aMultivariable analysis included adjustment for age
-
bMultivariable analysis included adjustment for Ki-67, tumor size, ER, PR, HER2, nodal status and age
